These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2935080)

  • 1. Dose range study in healthy volunteers of a hepatitis B vaccine produced in yeast.
    Kuwert E; Scheiermann N; Gesemann M; Paar D; Safary A; Simoen E; Hauser P; Andre F
    Antiviral Res; 1985; Suppl 1():281-8. PubMed ID: 2935080
    [No Abstract]   [Full Text] [Related]  

  • 2. Reactogenicity and immunogenicity of a new recombinant yeast-derived hepatitis B vaccine.
    Scheiermann N; Gesemann KM; Paar D; Maurer C
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 269(3):411-21. PubMed ID: 2975448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and side effects of low dose intradermally administered hepatitis B vaccine.
    Pathak UN; Dilawari JB; Chawla Y; Sokhey CS; Sharma BK; Ganguly NK
    Indian J Gastroenterol; 1988 Apr; 7(2):113-4. PubMed ID: 2966113
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity study of a plasma-derived heat-inactivated hepatitis-B vaccine in newborn babies: a randomised dose-response study.
    Ip HM; Wong VC; Reesink HW; Lelie PN; Yeung CY; Ma HK
    Asia Oceania J Obstet Gynaecol; 1988 Sep; 14(3):367-71. PubMed ID: 2972271
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune response after vaccination with recombinant hepatitis B vaccine as compared to that after plasma-derived vaccine.
    Heijtink RA; Kruining J; Bakker M; Schalm SW
    Antiviral Res; 1985; Suppl 1():273-9. PubMed ID: 2935079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules.
    Scheiermann N; Gesemann M; Maurer C; Just M; Berger R
    Vaccine; 1990 Mar; 8 Suppl():S44-6; discussion S60-2. PubMed ID: 2139282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine.
    Just M; Berger R; Scheiermann N
    Vaccine; 1988 Oct; 6(5):401-2. PubMed ID: 2973694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of recombinant hepatitis B vaccine.
    Ohmura T; Ohmizu A; Sumi A; Ohtani W; Uemura Y; Arimura H; Nishida M; Kohama Y; Okabe M; Mimura T
    Biochem Biophys Res Commun; 1987 Dec; 149(3):1172-8. PubMed ID: 2962578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yeast recombinant hepatitis B vaccine.
    Hilleman MR
    Infection; 1987; 15(1):3-7. PubMed ID: 2437037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Active hepatitis B immunization--current status of development and effectiveness].
    Baumgarten R; Fengler JD
    Z Arztl Fortbild (Jena); 1986; 80(10):393-4. PubMed ID: 2944291
    [No Abstract]   [Full Text] [Related]  

  • 11. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations.
    Hollinger FB
    Am J Med; 1989 Sep; 87(3A):36S-40S. PubMed ID: 2528297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is nonresponsiveness to hepatitis B vaccine due to latent hepatitis B virus infection?
    Luo KX; Wang LP; Nie J; Jiang S
    J Infect Dis; 1992 Apr; 165(4):777-8. PubMed ID: 1532408
    [No Abstract]   [Full Text] [Related]  

  • 13. [H-B-VAX II hepatitis B vaccine (recombinant) produced at the MSD Research Laboratories. Description of the vaccine].
    Przegl Epidemiol; 1991; 45(1-2):3-10. PubMed ID: 1839076
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of intradermal hepatitis B immunization of hospital staff.
    McKee CM; Duke P; McEvoy MB; Kelsey MC
    Int J STD AIDS; 1990 Jan; 1(1):32-4. PubMed ID: 2151564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of a recombinant hepatitis B vaccine.
    Jilg W; Lorbeer B; Schmidt M; Wilske B; Zoulek G; Deinhardt F
    Lancet; 1984 Nov; 2(8413):1174-5. PubMed ID: 6150233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing schedule for recombinant hepatitis B vaccine.
    Bryan JP; Sjogren MH; Macarthy P; Cox B; Kao TC; Perine PL
    J Infect Dis; 1991 Jun; 163(6):1384-5. PubMed ID: 1828076
    [No Abstract]   [Full Text] [Related]  

  • 17. Antibody response after intradermal administration of recombinant hepatitis B vaccine in children.
    Wiström J; Gustafsson A
    Scand J Infect Dis; 1990; 22(5):621-2. PubMed ID: 2148015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and immunological studies of an experimental series of vaccines against hepatitis B].
    Teokharova MP; Andonov AP; Mineva EG; Draganov PI
    Vopr Virusol; 1984; 29(4):483-7. PubMed ID: 6495708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a reduced dose of recombinant hepatitis B vaccine.
    Roumeliotou-Karayannis A; Dandolos E; Richardson SC; Papaevangelou G
    Vaccine; 1986 Jun; 4(2):93-4. PubMed ID: 2941929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of an anti-hepatitis-B vaccination in a population at risk].
    Stellato M; Carbi S; Tosolini S
    Boll Ist Sieroter Milan; 1989; 68(1):34-41. PubMed ID: 2535244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.